Document,Word,TFIDFVal
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk prediction,0.1480561735929628
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction models,0.13824153644933165
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx models,0.12157569155080113
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,validation and,0.09808650244038405
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,composite endpoints,0.09808650244038405
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,and composite,0.09808650244038405
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular death,0.09808650244038405
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx publications,0.09808650244038405
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,publications were,0.09808650244038405
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,variables were,0.09808650244038405
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation of,0.15319808696632656
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,myocardium and,0.12359925195083737
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,processing element,0.12359925195083737
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ventricular cavities,0.12359925195083737
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx patients,0.07966096314371385
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,pathological assessment,0.07299970928100977
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac pathological,0.07299970928100977
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,reproducible cardiac,0.07299970928100977
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,and reproducible,0.07299970928100977
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,efficient and,0.07299970928100977
Physiological Assessment of Coronary Lesions in 2020.,physiological assessment,0.1535490182789237
Physiological Assessment of Coronary Lesions in 2020.,coronary physiological,0.1238823811241975
Physiological Assessment of Coronary Lesions in 2020.,coronary physiology,0.1238823811241975
Physiological Assessment of Coronary Lesions in 2020.,of coronary,0.10597623645158007
Physiological Assessment of Coronary Lesions in 2020.,improve patient,0.07316692993176648
Physiological Assessment of Coronary Lesions in 2020.,and improve,0.07316692993176648
Physiological Assessment of Coronary Lesions in 2020.,refine clinical,0.07316692993176648
Physiological Assessment of Coronary Lesions in 2020.,further refine,0.07316692993176648
Physiological Assessment of Coronary Lesions in 2020.,will further,0.07316692993176648
Physiological Assessment of Coronary Lesions in 2020.,that will,0.07316692993176648
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,management of,0.2332441761487339
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,as hypertension,0.15048115317932845
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,conditions such,0.15048115317932845
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,of conditions,0.15048115317932845
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,ai in,0.15048115317932845
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,of ai,0.15048115317932845
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,and trials,0.15048115317932845
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,in and,0.15048115317932845
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,further improvements,0.15048115317932845
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,suggests further,0.15048115317932845
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base editors,0.1754912436971154
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse brain,0.14158523043210866
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base editing,0.14158523043210866
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dual aavs,0.14158523043210866
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",in vivo,0.1006553484486244
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",therapeutic interest,0.08362251791086737
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",of therapeutic,0.08362251791086737
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",multiple tissues,0.08362251791086737
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",into multiple,0.08362251791086737
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mutations into,0.08362251791086737
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nile virus,0.14853309252057567
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west nile,0.14853309252057567
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,non human,0.13597441830805151
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,in nature,0.11983556380519911
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,of wnv,0.11983556380519911
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv infection,0.11983556380519911
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,the pathology,0.11983556380519911
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,commonly affected,0.11983556380519911
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal models,0.10251435216115329
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,are addressed,0.07077681443238026
Photoplethysmography based atrial fibrillation detection: a review.,af detection,0.12852796287445759
Photoplethysmography based atrial fibrillation detection: a review.,of af,0.12852796287445759
Photoplethysmography based atrial fibrillation detection: a review.,cardiac rhythm,0.12852796287445759
Photoplethysmography based atrial fibrillation detection: a review.,wearable devices,0.10396967976239399
Photoplethysmography based atrial fibrillation detection: a review.,clinical applications,0.07591068534984166
Photoplethysmography based atrial fibrillation detection: a review.,towards clinical,0.07591068534984166
Photoplethysmography based atrial fibrillation detection: a review.,challenges towards,0.07591068534984166
Photoplethysmography based atrial fibrillation detection: a review.,and challenges,0.07591068534984166
Photoplethysmography based atrial fibrillation detection: a review.,limitations and,0.07591068534984166
Photoplethysmography based atrial fibrillation detection: a review.,their limitations,0.07591068534984166
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow map,0.16970771388640588
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",single cell,0.15532149466160353
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map analysis,0.11011572105887328
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",we perform,0.11011572105887328
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",use the,0.11011572105887328
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass cytometry,0.11011572105887328
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",time course,0.11011572105887328
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",of single,0.11011572105887328
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dimensional single,0.11011572105887328
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",high dimensional,0.11011572105887328
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,using msspe,0.11946514269145042
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,and or,0.09663852402711026
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,field use,0.07055803775543114
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,and field,0.07055803775543114
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,laboratory and,0.07055803775543114
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,diagnostic laboratory,0.07055803775543114
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,for diagnostic,0.07055803775543114
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,applicable for,0.07055803775543114
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,directly applicable,0.07055803775543114
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,method directly,0.07055803775543114
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,loci auc,0.12121842793734253
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx loci,0.12121842793734253
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,of asthma,0.12121842793734253
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,controls from,0.12121842793734253
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma and,0.12121842793734253
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,with asthma,0.12121842793734253
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam markers,0.12121842793734253
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,auc xxx,0.1109692456225763
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,subjects with,0.1109692456225763
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx subjects,0.1109692456225763
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg signal,0.1663635529518116
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic patients,0.13422106701141195
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,non invasive,0.12287249394632081
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,of ecg,0.07927312436419338
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,excerpts of,0.07927312436419338
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,short excerpts,0.07927312436419338
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,using short,0.07927312436419338
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,system using,0.07927312436419338
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,alarming system,0.07927312436419338
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia alarming,0.07927312436419338
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stage nsclc,0.1457803222851422
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,with early,0.1457803222851422
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,early stage,0.13345439852561192
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac dosimetry,0.12820563161789506
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv vxxxgy,0.12820563161789506
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann analysis,0.12820563161789506
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetry to,0.10343549634101816
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,received rv,0.10343549634101816
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,had received,0.10343549634101816
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,who had,0.10343549634101816
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl sulfate,0.16904967782729868
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,various tissues,0.10252530296494412
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,in various,0.10252530296494412
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase expression,0.10252530296494412
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,sulfate levels,0.10252530296494412
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,serum indoxyl,0.10252530296494412
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,of galactosidase,0.10252530296494412
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal tubules,0.10252530296494412
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase in,0.10252530296494412
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,in galactosidase,0.10252530296494412
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life expectancy,0.21031046499252673
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain age,0.21031046499252673
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,an individual,0.14922156153327032
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx years,0.10608414611000945
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx xxx,0.09970820998918785
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,expectancy copyright,0.08813265807401388
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age is,0.08813265807401388
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,for age,0.08813265807401388
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,normal for,0.08813265807401388
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,patterns normal,0.08813265807401388
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru model,0.15526109991074868
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf screening,0.12526367780461134
Gated recurrent unit-based heart sound analysis for heart failure screening.,of hs,0.12526367780461134
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed model,0.11467246413286486
Gated recurrent unit-based heart sound analysis for heart failure screening.,early screening,0.11467246413286486
Gated recurrent unit-based heart sound analysis for heart failure screening.,the proposed,0.10715787844364481
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf with,0.10715787844364481
Gated recurrent unit-based heart sound analysis for heart failure screening.,ejection fraction,0.08322331358798954
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf early,0.07398274600273382
Gated recurrent unit-based heart sound analysis for heart failure screening.,analysis for,0.07398274600273382
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd risk,0.18009785978295567
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som based,0.1583859845044272
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroup with,0.12778481501891778
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,the som,0.12778481501891778
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein quartiles,0.12778481501891778
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,by apolipoprotein,0.12778481501891778
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based subgroups,0.12778481501891778
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein profiles,0.12778481501891778
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,cohort xxx,0.1169804357799415
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk assessment,0.1169804357799415
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angptlxxx and,0.1614682296205125
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,and angptlxxx,0.14766043062661732
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,of angptlxxx,0.12985908164222293
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg rich,0.12985908164222293
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich lipoproteins,0.11887932034992817
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,monoclonal antibodies,0.10476948940967794
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,marked reduction,0.10476948940967794
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,function mutations,0.10476948940967794
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoproteins and,0.10476948940967794
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,evidence has,0.10476948940967794
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast cancer,0.20665207175521275
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,ikkε and,0.16969146185768996
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,of breast,0.16969146185768996
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,with obesity,0.1369060029624562
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer associated,0.1369060029624562
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,the breast,0.12533041492502153
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cancer and,0.11711740450842878
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,and its,0.11711740450842878
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,xxx license,0.08085889078891513
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cc by,0.08085889078891513
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older adults,0.17638699169527752
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived ubiquity,0.16130342923726165
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,adults in,0.16130342923726165
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology anxiety,0.14185733508700893
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,in general,0.14185733508700893
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived usefulness,0.11444960474178434
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,and perceived,0.11444960474178434
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,use and,0.11444960474178434
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,ease of,0.11444960474178434
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived ease,0.11444960474178434
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary behaviours,0.15026881606888562
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx value,0.1404552039775692
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence of,0.12854873662017996
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,value xxx,0.12015359869987488
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,higher prevalence,0.11295958247182732
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx vs,0.10827792090798102
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs xxx,0.10827792090798102
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd risk,0.10340869673065879
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,of undiagnosed,0.0911350798869023
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diagnosed hypertension,0.0911350798869023
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",exxx neta,0.17343895468435278
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",months xxx,0.1482493044704312
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx months,0.13113683556052672
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx at,0.12682112824897868
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",at xxx,0.1142864487005842
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",of ldl,0.10518731300453864
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein component,0.10518731300453864
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",on hdl,0.10518731300453864
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",the greatest,0.10518731300453864
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",menopausal women,0.10518731300453864
Heart Failure With Mid-range Ejection Fraction.,failure with,0.153802402142549
Heart Failure With Mid-range Ejection Fraction.,ejection fraction,0.13061918458499278
Heart Failure With Mid-range Ejection Fraction.,and hfpef,0.1275659792527395
Heart Failure With Mid-range Ejection Fraction.,hfref and,0.1275659792527395
Heart Failure With Mid-range Ejection Fraction.,at others,0.1275659792527395
Heart Failure With Mid-range Ejection Fraction.,ef xxx,0.1275659792527395
Heart Failure With Mid-range Ejection Fraction.,fraction hfmref,0.1275659792527395
Heart Failure With Mid-range Ejection Fraction.,range ejection,0.1275659792527395
Heart Failure With Mid-range Ejection Fraction.,mid range,0.1275659792527395
Heart Failure With Mid-range Ejection Fraction.,management and,0.1275659792527395
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv index,0.15097201769163537
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling to,0.12180327327648843
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,as is,0.1115046414959203
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,of coronary,0.10419764596213626
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary prediction,0.07193897534425006
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,classification models,0.07193897534425006
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,algorithm classification,0.07193897534425006
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,efficient algorithm,0.07193897534425006
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,obtain efficient,0.07193897534425006
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,and enabling,0.07193897534425006
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell subsets,0.17890298320919243
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory cell,0.17890298320919243
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory cells,0.17890298320919243
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung and,0.1637764935923302
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,between memory,0.14433780038839358
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,clonal overlap,0.14433780038839358
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,the clonal,0.14433780038839358
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,within the,0.1112710422390781
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune responses,0.08524823006861058
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,in immune,0.08524823006861058
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generation of,0.16026125442855413
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,mesenchyme free,0.14123978627409986
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,of mesenchyme,0.14123978627409986
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed differentiation,0.14123978627409986
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic fibrosis,0.14123978627409986
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,screening applications,0.08341849302633575
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,therapeutic screening,0.08341849302633575
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,modeling and,0.08341849302633575
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,disease modeling,0.08341849302633575
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,for disease,0.08341849302633575
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref the,0.1559181883245142
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,to bnp,0.12579381259947228
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,lpc xxx,0.12579381259947228
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic panel,0.12579381259947228
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolomics and,0.12579381259947228
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,and machine,0.11515777531256771
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,comparable to,0.10761138676227382
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,the study,0.0863393121884647
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,ejection fraction,0.08357552721487534
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,proposed markers,0.07429585215259941
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce us,0.18553399054325084
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us imaging,0.14921371022639046
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative maps,0.12038468188473292
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,the uca,0.12038468188473292
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative dce,0.12038468188473292
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,have been,0.092805411935675
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,models of,0.092805411935675
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,biology published,0.07110113241597825
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,medicine biology,0.07110113241597825
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,in medicine,0.07110113241597825
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,contractile function,0.157486243327533
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac contractile,0.157486243327533
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,of chast,0.13850033379294904
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,of cardiac,0.13276012410812615
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,function and,0.11203659522327396
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,was an,0.11174119723513579
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression level,0.11174119723513579
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast at,0.11174119723513579
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,the chast,0.11174119723513579
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami patients,0.11174119723513579
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,of individuals,0.12709918153726515
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,clinical biomarkers,0.11201373220212292
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health and,0.11201373220212292
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures of,0.11201373220212292
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarker signatures,0.11201373220212292
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx individuals,0.11201373220212292
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel biomarkers,0.11201373220212292
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stratification of,0.10254281938274216
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data driven,0.10254281938274216
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential of,0.09582309979798627
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food allergy,0.17844580669979188
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,in food,0.1525289793002645
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food allergic,0.13414069762429306
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reaction phenotypes,0.13414069762429306
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,of severe,0.10822387022476565
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen exposure,0.10822387022476565
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,following allergen,0.10822387022476565
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exist in,0.09907339537026111
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,future copyright,0.06391876114926678
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,the future,0.06391876114926678
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt score,0.15346685149149306
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients undergoing,0.14049102127347954
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,semmelweis crt,0.13496550370764177
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt implantation,0.13496550370764177
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,undergoing crt,0.13496550370764177
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ci xxx,0.12937179667255413
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx ci,0.12397731074719677
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx year,0.11830869300112597
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,the semmelweis,0.10888931857940996
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,deaths in,0.10888931857940996
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,the proposed,0.12613145787025937
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,specificity of,0.11895616856161217
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,sensitivity of,0.11895616856161217
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed method,0.11895616856161217
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,the false,0.11895616856161217
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx for,0.09170416080195719
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,of xxx,0.08527393233684327
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,tachycardia arrhythmia,0.07025742943520825
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ventricular tachycardia,0.07025742943520825
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm type,0.07025742943520825
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood glucose,0.1326494971800287
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,the en,0.12470730780175525
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,north china,0.12470730780175525
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,in north,0.12470730780175525
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glucose control,0.12470730780175525
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,and accuracy,0.1006130707133945
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,en and,0.1006130707133945
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,dimensional reduction,0.1006130707133945
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,bp ann,0.1006130707133945
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,svm and,0.1006130707133945
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims only,0.1262910916979081
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,and home,0.1262910916979081
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,network xxx,0.11549143152337946
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,ci xxx,0.11489464481756123
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx ci,0.11010382053971648
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf hospitalization,0.10572647451462908
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cost xxx,0.10156824798307378
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims emr,0.10156824798307378
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,vs claims,0.10156824798307378
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,from network,0.10156824798307378
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,fhs and,0.15914977031139266
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,in fhs,0.15914977031139266
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,of ad,0.15914977031139266
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,nacc respectively,0.12840103259879102
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,and nacc,0.12840103259879102
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,accuracy in,0.12840103259879102
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,delayed recall,0.12840103259879102
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,and delayed,0.12840103259879102
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,immediate and,0.12840103259879102
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed using,0.12840103259879102
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care utilization,0.1725372547696298
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd patients,0.1296991403105104
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health care,0.1187329022745083
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,centered care,0.10464044975032481
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,of hnd,0.10464044975032481
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically significant,0.09579295795192783
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,the two,0.09579295795192783
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,between the,0.08951556262082576
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients and,0.08464643652183976
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,that the,0.07182057902403181
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave morphology,0.16849814210414202
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,and sex,0.1355128129136616
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc age,0.1355128129136616
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts diagnosis,0.1355128129136616
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,age and,0.12405502098241462
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model with,0.10933088420068779
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,cut offs,0.10933088420068779
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc cut,0.10933088420068779
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,leads and,0.10933088420068779
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,hg polynomials,0.10933088420068779
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers xxx,0.13327677240618785
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sacubitril valsartan,0.122008040729345
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf guidelines,0.10752686079851388
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc hf,0.10752686079851388
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,low proportion,0.10752686079851388
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,target doses,0.10752686079851388
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,antagonists xxx,0.10752686079851388
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,of complexity,0.10752686079851388
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,linx registry,0.10752686079851388
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,the linx,0.10752686079851388
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,prevalence of,0.1309639856028345
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx mg,0.128163384822414
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria was,0.1231227136982789
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,lercanidipine enalapril,0.1231227136982789
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,the prevalence,0.11976472743983059
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,subjects with,0.11271252144240587
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,of subjects,0.10532637249172445
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,in xxx,0.10342717387349976
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,was significantly,0.09959723027113294
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,reduced with,0.09933463016812558
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc patients,0.13988640047303463
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,of hcc,0.13988640047303463
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features were,0.128058815788092
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognostic model,0.11285946710524335
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,was able,0.11285946710524335
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features was,0.11285946710524335
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image features,0.11285946710524335
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,patients survival,0.11285946710524335
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,extracted from,0.11285946710524335
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,were extracted,0.11285946710524335
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive impairment,0.12702751539482884
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,for heart,0.12702751539482884
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,in xxx,0.11656288718705461
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,the use,0.11216943319572448
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,acei arbs,0.11195057214090358
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people prescribed,0.11195057214090358
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive function,0.11195057214090358
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among people,0.11195057214090358
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx people,0.11195057214090358
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,diuretics was,0.11195057214090358
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx diabetes,0.15804647949906214
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,and cvd,0.14756958542251983
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes and,0.14756958542251983
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type xxx,0.1396561039604935
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,information on,0.1297791883713877
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,selected glycans,0.104705032021817
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predictive for,0.104705032021817
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,for cvd,0.104705032021817
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prediction scores,0.104705032021817
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,for type,0.104705032021817
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple igfxxx,0.14011246259395893
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,igfxxx signaling,0.14011246259395893
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,of multiple,0.12826576405041212
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,skeletal muscle,0.12826576405041212
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,class xxx,0.1130418526010022
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mouse skeletal,0.1130418526010022
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,and mouse,0.1130418526010022
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,human and,0.1130418526010022
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,variants can,0.1130418526010022
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,mrna variants,0.1130418526010022
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,in group,0.1442677512965966
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,than those,0.11670354911217423
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,均p xxx,0.11557292669834156
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group at,0.11557292669834156
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group xxx,0.11322705305564447
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,at xxx,0.10539844485183568
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,were significantly,0.10432696129908761
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx il,0.10432696129908761
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,those in,0.09886784299783065
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il xxx,0.09865218123608314
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,to hfd,0.15405972419336772
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hfd xxx,0.1473793539897274
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx fold,0.14103376578515772
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,decrease compared,0.13966743255950184
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apo ai,0.13966743255950184
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,both mimetics,0.11938263680036472
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold auc,0.11938263680036472
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf xxx,0.11938263680036472
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic peptides,0.11938263680036472
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic inflammation,0.11938263680036472
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,of potassium,0.18165166714832154
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium channels,0.18165166714832154
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand peptides,0.16611790107691018
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides of,0.14609139352118772
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,pplk is,0.11786561642668
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides with,0.11786561642668
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,can predict,0.10789991886769355
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,that can,0.10789991886769355
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,prediction of,0.09534462478681686
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,the prediction,0.09534462478681686
Machine learning: a long way from implementation in cardiovascular disease.,none declared,0.2856191982217762
Machine learning: a long way from implementation in cardiovascular disease.,interests none,0.2856191982217762
Machine learning: a long way from implementation in cardiovascular disease.,competing interests,0.2856191982217762
Machine learning: a long way from implementation in cardiovascular disease.,statement competing,0.2856191982217762
Machine learning: a long way from implementation in cardiovascular disease.,interest statement,0.2856191982217762
Machine learning: a long way from implementation in cardiovascular disease.,conflict of,0.2856191982217762
Machine learning: a long way from implementation in cardiovascular disease.,xxx conflict,0.2856191982217762
Machine learning: a long way from implementation in cardiovascular disease.,heartjnl xxx,0.2856191982217762
Machine learning: a long way from implementation in cardiovascular disease.,xxx heartjnl,0.2856191982217762
Machine learning: a long way from implementation in cardiovascular disease.,of interest,0.2614697080412446
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,term xxx,0.10995239732494361
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,between phenogroups,0.10995239732494361
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,composite end,0.10995239732494361
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,the composite,0.10995239732494361
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteomics and,0.10995239732494361
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx days,0.10068085108016873
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,end point,0.10065577316222583
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,using machine,0.10065577316222583
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical and,0.10065577316222583
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx xxx,0.09776983545464929
Machine Learning in Fetal Cardiology: What to Expect.,fetal cardiac,0.15540981652260027
Machine Learning in Fetal Cardiology: What to Expect.,of fetal,0.12538366143065727
Machine Learning in Fetal Cardiology: What to Expect.,aid in,0.12538366143065727
Machine Learning in Fetal Cardiology: What to Expect.,fetal heart,0.12538366143065727
Machine Learning in Fetal Cardiology: What to Expect.,the fetal,0.12538366143065727
Machine Learning in Fetal Cardiology: What to Expect.,to help,0.12538366143065727
Machine Learning in Fetal Cardiology: What to Expect.,in fetal,0.12538366143065727
Machine Learning in Fetal Cardiology: What to Expect.,improve the,0.11478230298076891
Machine Learning in Fetal Cardiology: What to Expect.,to perform,0.10142617088792698
Machine Learning in Fetal Cardiology: What to Expect.,the diagnosis,0.10142617088792698
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam cells,0.21818115197635776
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,living foam,0.16401042129175833
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,three dimensional,0.13232257520460275
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive index,0.13232257520460275
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,label free,0.13232257520460275
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,metabolic diseases,0.07815184452000326
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,related metabolic,0.07815184452000326
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,ld related,0.07815184452000326
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,against ld,0.07815184452000326
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,drugs against,0.07815184452000326
Supervised machine learning models applied to disease diagnosis and prognosis.,and heart,0.233160867130314
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer and,0.21788163397985583
Supervised machine learning models applied to disease diagnosis and prognosis.,heart disease,0.19634676436368
Supervised machine learning models applied to disease diagnosis and prognosis.,important variables,0.18071423861160915
Supervised machine learning models applied to disease diagnosis and prognosis.,ml algorithms,0.18071423861160915
Supervised machine learning models applied to disease diagnosis and prognosis.,disease data,0.18071423861160915
Supervised machine learning models applied to disease diagnosis and prognosis.,the important,0.16543460489649506
Supervised machine learning models applied to disease diagnosis and prognosis.,breast cancer,0.16543460489649506
Supervised machine learning models applied to disease diagnosis and prognosis.,aims press,0.10673274047672845
Supervised machine learning models applied to disease diagnosis and prognosis.,licensee aims,0.10673274047672845
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,non genomic,0.15239991873290448
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,of gαs,0.10813229789433257
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,knockdown of,0.10813229789433257
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,the camp,0.10813229789433257
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp levels,0.10813229789433257
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp production,0.10813229789433257
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic actions,0.10813229789433257
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,have been,0.08335996152104565
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,of federation,0.06386467705576064
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inc on,0.06386467705576064
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pkcδ inhibition,0.1981125917494484
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved survival,0.14892454889756043
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pkcδ inhibitor,0.12015138834534064
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pathogen clearance,0.12015138834534064
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",and improved,0.12015138834534064
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",an important,0.09262556427826323
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",injury xxx,0.07096334549345264
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organ injury,0.07096334549345264
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased organ,0.07096334549345264
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",and decreased,0.07096334549345264
Innovations in pharmacological treatment of heart failure.,indicated in,0.14553816859927193
Innovations in pharmacological treatment of heart failure.,be added,0.14553816859927193
Innovations in pharmacological treatment of heart failure.,ace inhibitors,0.14553816859927193
Innovations in pharmacological treatment of heart failure.,decrease of,0.14553816859927193
Innovations in pharmacological treatment of heart failure.,added to,0.12450186401199013
Innovations in pharmacological treatment of heart failure.,angiotensin receptor,0.11772968655273623
Innovations in pharmacological treatment of heart failure.,should be,0.11772968655273623
Innovations in pharmacological treatment of heart failure.,to the,0.0919396689838688
Innovations in pharmacological treatment of heart failure.,drugs pmid,0.08595718687086648
Innovations in pharmacological treatment of heart failure.,perspective drugs,0.08595718687086648
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd patients,0.15750520243472158
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission risk,0.15750520243472158
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,the readmission,0.11175464928841355
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,of copd,0.11175464928841355
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,day readmission,0.11175464928841355
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,the hospital,0.11175464928841355
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predict the,0.10678375120640556
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,the xxx,0.10233113125556875
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx day,0.10230564228040516
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ai and,0.10230564228040516
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo mφ,0.1609856279070223
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected mice,0.11420185097963086
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription factors,0.10971028754789533
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tc induced,0.10971028754789533
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,the tc,0.10971028754789533
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cdxxx cdxxx,0.10971028754789533
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mφ of,0.10971028754789533
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,of proinflammatory,0.10971028754789533
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,of chagas,0.10043413409484916
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas disease,0.10043413409484916
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood disorders,0.17923457517745714
Mood disorders and increased risk of non-communicable disease in adults with HIV.,disorders were,0.13473362808208786
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic syndrome,0.13473362808208786
Mood disorders and increased risk of non-communicable disease in adults with HIV.,year of,0.13473362808208786
Mood disorders and increased risk of non-communicable disease in adults with HIV.,and multimorbidity,0.13473362808208786
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds and,0.13473362808208786
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident ncds,0.13473362808208786
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ashr xxx,0.10870224278472075
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx incident,0.10870224278472075
Mood disorders and increased risk of non-communicable disease in adults with HIV.,following multimorbidity,0.10870224278472075
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial fibrillation,0.1442451897113697
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",most relevant,0.14356032735052277
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",or xxx,0.13415269501606764
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac arrhythmia,0.1265210984696682
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",for atrial,0.1265210984696682
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study outcomes,0.1265210984696682
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",predictors for,0.1265210984696682
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",relevant predictors,0.1265210984696682
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",identify the,0.1265210984696682
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",and betahistine,0.1265210984696682
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lumen and,0.13370062184103382
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent deployment,0.13370062184103382
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically obtained,0.10786881985377456
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,and automatically,0.10786881985377456
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually and,0.10786881985377456
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,between manually,0.10786881985377456
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lesions the,0.10786881985377456
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment calcification,0.10786881985377456
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,using the,0.07166643019263604
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx xxx,0.07027714446945822
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx kpa,0.1289425873686685
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress xxx,0.1289425873686685
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv pressure,0.1289425873686685
Prediction of Left Ventricular Mechanics Using Machine Learning.,of lv,0.11804031690891412
Prediction of Left Ventricular Mechanics Using Machine Learning.,the lv,0.11804031690891412
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml model,0.10403006760049144
Prediction of Left Ventricular Mechanics Using Machine Learning.,predict lv,0.10403006760049144
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber stress,0.10403006760049144
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx mmhg,0.10403006760049144
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure xxx,0.10403006760049144
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hlox xxx,0.13591783104338642
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",and block,0.13591783104338642
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",properties and,0.13591783104338642
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hbace xxx,0.12442579428053281
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",block neurodegeneration,0.0802752605349032
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",regeneration and,0.0802752605349032
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neuronal regeneration,0.0802752605349032
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",to neuronal,0.0802752605349032
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",synergistically contribute,0.0802752605349032
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",could synergistically,0.0802752605349032
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,the patients,0.14257662607101504
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,the tgf,0.12528630443728092
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,of connective,0.12528630443728092
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,il xxxa,0.12528630443728092
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,to tgf,0.10108020155327732
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,further accounting,0.10108020155327732
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,il xxxf,0.10108020155327732
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,and il,0.10108020155327732
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,patients fibroblasts,0.10108020155327732
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,signaling pathway,0.10108020155327732
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,in hf,0.1730292650941163
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado induced,0.1478991167233252
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,axxxr and,0.1478991167233252
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rate slowing,0.13006899270091155
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,and girk,0.13006899270091155
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,in ctl,0.10493884433012042
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slowing in,0.10493884433012042
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced rate,0.10493884433012042
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,prevented ado,0.10493884433012042
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk mrna,0.10493884433012042
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical phase,0.14332951427828744
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,that slow,0.12605028318974146
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,organize the,0.10169657480036108
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could organize,0.10169657480036108
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiration could,0.10169657480036108
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced inspiration,0.10169657480036108
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow paced,0.10169657480036108
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain areas,0.10169657480036108
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,widespread brain,0.10169657480036108
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,to normal,0.10169657480036108
Implications for REDUCE IT in clinical practice.,high risk,0.1638530739923466
Implications for REDUCE IT in clinical practice.,on statin,0.15453190043375986
Implications for REDUCE IT in clinical practice.,residual risk,0.15453190043375986
Implications for REDUCE IT in clinical practice.,statin therapy,0.15453190043375986
Implications for REDUCE IT in clinical practice.,risk patients,0.14146601888469718
Implications for REDUCE IT in clinical practice.,in patients,0.09679347480553059
Implications for REDUCE IT in clinical practice.,risk copyright,0.09126902977368699
Implications for REDUCE IT in clinical practice.,high ascvd,0.09126902977368699
Implications for REDUCE IT in clinical practice.,at high,0.09126902977368699
Implications for REDUCE IT in clinical practice.,therapy in,0.09126902977368699
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,revascularization and,0.15189498421518172
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,repeat revascularization,0.15189498421518172
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,any repeat,0.15189498421518172
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,re mi,0.15189498421518172
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,of maces,0.12254791685621583
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,incidences of,0.12254791685621583
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cumulative incidences,0.12254791685621583
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,the cumulative,0.12254791685621583
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,occurrences of,0.12254791685621583
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,the occurrences,0.12254791685621583
Women had favourable reverse left ventricle remodelling after TAVR.,after tavr,0.16109271091333907
Women had favourable reverse left ventricle remodelling after TAVR.,post tavr,0.1473170240373465
Women had favourable reverse left ventricle remodelling after TAVR.,the lvmi,0.12955707477333223
Women had favourable reverse left ventricle remodelling after TAVR.,lv mass,0.12955707477333223
Women had favourable reverse left ventricle remodelling after TAVR.,regression of,0.12955707477333223
Women had favourable reverse left ventricle remodelling after TAVR.,lv remodelling,0.12955707477333223
Women had favourable reverse left ventricle remodelling after TAVR.,clinical investigation,0.1045258321694468
Women had favourable reverse left ventricle remodelling after TAVR.,with greater,0.1045258321694468
Women had favourable reverse left ventricle remodelling after TAVR.,of lvmi,0.1045258321694468
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi regression,0.1045258321694468
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl levels,0.12452750272136896
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,in fh,0.1097472869055479
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,this risk,0.1097472869055479
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh is,0.1097472869055479
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cardiovascular disease,0.09670528233755449
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic cardiovascular,0.09388424989475745
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk is,0.09388424989475745
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,of these,0.08877749261074598
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,patients copyright,0.06481851558188406
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh patients,0.06481851558188406
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",this syndrome,0.12853715794472534
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whim syndrome,0.12853715794472534
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",in xxx,0.0949583956544513
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",of this,0.07836581513429294
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",family concerns,0.07591611610646656
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",and family,0.07591611610646656
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patient and,0.07591611610646656
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",for patient,0.07591611610646656
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",source for,0.07591611610646656
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",and source,0.07591611610646656
Prime time for ticagrelor monotherapy.,nov xxx,0.39411065291552905
Prime time for ticagrelor monotherapy.,xxx nov,0.39411065291552905
Prime time for ticagrelor monotherapy.,engl med,0.39411065291552905
Prime time for ticagrelor monotherapy.,on engl,0.39411065291552905
Prime time for ticagrelor monotherapy.,comment on,0.39411065291552905
Prime time for ticagrelor monotherapy.,med xxx,0.36078806325110346
Prime time for ticagrelor monotherapy.,xxx xxx,0.30531285545812653
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir xxxa,0.1914642014962185
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il xxx,0.16343240277654
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil inhibited,0.1439268427416116
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,the mir,0.1439268427416116
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,atdcxxx cells,0.1439268427416116
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,in atdcxxx,0.1439268427416116
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory injury,0.1439268427416116
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxx induced,0.1317576331886717
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jnk and,0.11611927048683797
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa mimic,0.11611927048683797
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compound xxx,0.1442958814634495
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx μm,0.14036042899858295
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",icxxx xxx,0.13209546918658646
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ascertained by,0.11641700860396002
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",studies copyright,0.06875776066051117
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pharmacokinetic studies,0.06875776066051117
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",by pharmacokinetic,0.06875776066051117
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",characteristics ascertained,0.06875776066051117
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",absorption characteristics,0.06875776066051117
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",oral absorption,0.06875776066051117
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",rxxx subtype,0.17841981700761902
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound xxxc,0.1569102398324331
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",against hiv,0.1569102398324331
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",anti hiv,0.1569102398324331
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",confirmed by,0.126594193509597
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype and,0.126594193509597
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead compound,0.126594193509597
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",the lead,0.126594193509597
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",most active,0.126594193509597
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv xxxugxxx,0.126594193509597
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",able to,0.15880931645735014
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",is able,0.13951703363530596
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",that memantine,0.11256146426628658
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infection of,0.11256146426628658
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",the infection,0.11256146426628658
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",memantine is,0.11256146426628658
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",as trypanocidal,0.11256146426628658
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",that were,0.10304423995878656
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chagas disease,0.10304423995878656
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",these results,0.09105395535431543
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,of dap,0.18810452145076265
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mmp xxx,0.13400220654971257
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap on,0.13400220654971257
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,il xxxβ,0.12267213843318098
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect of,0.1174642814693232
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,il xxx,0.1083979407347826
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx mmp,0.10811213649780482
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxxβ in,0.10811213649780482
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa groups,0.10811213649780482
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbit chondrocytes,0.10811213649780482
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,one xxx,0.14260125906979815
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without one,0.14260125906979815
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,with without,0.14260125906979815
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,or without,0.14260125906979815
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,with or,0.14260125906979815
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,groups with,0.14260125906979815
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi and,0.14260125906979815
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,perioperative use,0.14260125906979815
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx vs,0.13625828962990855
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,vs xxx,0.13625828962990855
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,rec xxx,0.384116496620992
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx rec,0.384116496620992
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,for medline,0.32859572363279044
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,indexed for,0.32859572363279044
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx indexed,0.32859572363279044
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx pmid,0.32859572363279044
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,doi xxx,0.32859572363279044
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,pmid xxx,0.310722026958025
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx xxx,0.26169659543360796
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",μg ml,0.16504763969124936
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx μg,0.16504763969124936
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit extracts,0.16504763969124936
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus fruit,0.16504763969124936
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",all extracts,0.13315939647845398
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ecxxx xxx,0.13315939647845398
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aortic rings,0.13315939647845398
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat aortic,0.13315939647845398
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",fruit extract,0.13315939647845398
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase activity,0.13315939647845398
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",hiv xxx,0.1834159229719092
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",reproductive tract,0.14953881042877917
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female reproductive,0.13151101151300085
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",the upper,0.13151101151300085
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",on hiv,0.13151101151300085
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",of hiv,0.1203915773120163
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells from,0.11250221319297819
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",levonorgestrel containing,0.10610225602802528
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fusion susceptibility,0.10610225602802528
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",we studied,0.10610225602802528
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",renin activity,0.2111536130685045
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma renin,0.2111536130685045
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated plasma,0.2001045751292687
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cachexia sarcopenia,0.12135948706603654
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",normalization of,0.12135948706603654
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",the normalization,0.12135948706603654
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac systolic,0.12135948706603654
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",pathologically elevated,0.12135948706603654
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf by,0.12135948706603654
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage hf,0.12135948706603654
Sensor Networks for Aerospace Human-Machine Systems.,sensor networks,0.12624484587348675
Sensor Networks for Aerospace Human-Machine Systems.,human machine,0.12624484587348675
Sensor Networks for Aerospace Human-Machine Systems.,networks for,0.10185354674854051
Sensor Networks for Aerospace Human-Machine Systems.,of sensor,0.10185354674854051
Sensor Networks for Aerospace Human-Machine Systems.,cognitive states,0.10185354674854051
Sensor Networks for Aerospace Human-Machine Systems.,operator cognitive,0.10185354674854051
Sensor Networks for Aerospace Human-Machine Systems.,the operator,0.10185354674854051
Sensor Networks for Aerospace Human-Machine Systems.,machine systems,0.10185354674854051
Sensor Networks for Aerospace Human-Machine Systems.,to support,0.10185354674854051
Sensor Networks for Aerospace Human-Machine Systems.,physical systems,0.10185354674854051
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving detection,0.1261048962071881
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detection system,0.11090219595432607
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,retest reliability,0.11090219595432607
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,test retest,0.11090219595432607
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,the craving,0.11090219595432607
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological signals,0.11090219595432607
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,for gaming,0.11090219595432607
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving for,0.11090219595432607
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,third experiment,0.08947519339894121
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,the third,0.08947519339894121
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,trpvxxx is,0.1874823764312323
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular dystrophy,0.1874823764312323
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,trpvxxx inhibitors,0.15125960081968284
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,for cardiomyopathy,0.15125960081968284
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,of trpvxxx,0.15125960081968284
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,and their,0.10381790349462655
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,with muscular,0.08933635690764896
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy associated,0.08933635690764896
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,their therapeutic,0.08933635690764896
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inhibitors and,0.08933635690764896
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft reperfusion,0.1508288924154306
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc subsets,0.13264556639218408
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,after allograft,0.13264556639218408
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd development,0.13264556639218408
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilcxxx frequencies,0.1070176077608119
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,of donor,0.1070176077608119
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,transplant recipients,0.1070176077608119
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,interstitial lung,0.1070176077608119
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,with pgd,0.1070176077608119
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc populations,0.1070176077608119
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,catenin pathway,0.1947806963622207
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,wnt catenin,0.1947806963622207
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,the wnt,0.18206014497317494
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pathway and,0.134039905856941
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,chronic inflammation,0.134039905856941
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,oxidative stress,0.12525615497172485
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,clock disruption,0.11813065935955694
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian clock,0.11813065935955694
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,and pparγ,0.11813065935955694
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin in,0.11813065935955694
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,of lsdxxx,0.1452463766816235
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,of oleacein,0.1452463766816235
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,inhibitor of,0.11718386216117825
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lsdxxx with,0.11718386216117825
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,the lsdxxx,0.11718386216117825
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,to target,0.11718386216117825
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,demethylase xxxa,0.11718386216117825
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lysine specific,0.11718386216117825
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,target the,0.10727580784901405
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ability of,0.09479313567055274
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,of igfxxxr,0.16889811745486924
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,paraquat induced,0.16889811745486924
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,that vasicinone,0.13626593769356302
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,the paraquat,0.13626593769356302
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,syxxxy cells,0.13626593769356302
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,in sh,0.13626593769356302
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,of vasicinone,0.13626593769356302
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone is,0.13626593769356302
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sh syxxxy,0.12474446804180504
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,neurodegenerative disorders,0.08048085793019961
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl levels,0.17835135033543714
Practical guide for the use of PCSK9 inhibitors in Portugal.,in clinical,0.146571509373456
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular events,0.138233438903824
Practical guide for the use of PCSK9 inhibitors in Portugal.,use in,0.12654561435907144
Practical guide for the use of PCSK9 inhibitors in Portugal.,lowering therapy,0.12654561435907144
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipid lowering,0.12654561435907144
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical practice,0.10656514632848225
Practical guide for the use of PCSK9 inhibitors in Portugal.,of patients,0.0948773217837297
Practical guide for the use of PCSK9 inhibitors in Portugal.,españa all,0.08164289583975118
Practical guide for the use of PCSK9 inhibitors in Portugal.,elsevier españa,0.08164289583975118
